NEUMORA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | — | $176.1M | $200.9M | $142.7M | $91.7M |
| SG&A Expense | — | $60.1M | $62.5M | $45.5M | $31.1M |
| Operating Income | — | $-241.2M | $-263.5M | $-252.1M | $-135.9M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | — | $2.0M | — | — | — |
| Pretax Income | — | $-236.8M | $-243.6M | $-235.7M | $-130.9M |
| Income Tax Expense | — | $130.0K | $178.0K | $268.0K | — |
| Net Income | — | $-236.9M | $-243.8M | $-235.9M | $-130.9M |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | — | $-1.45 | $-1.53 | $-1.82 | $-1.20 |
| EPS (Diluted) | — | $-1.45 | $-1.53 | $-1.82 | $-1.20 |
| Shares Outstanding (Basic) | 182.0M | 163.4M | 159.4M | 130.0M | 108.8M |
| Shares Outstanding (Diluted) | 182.0M | 163.4M | 159.4M | 130.0M | 108.8M |
| Dividends Per Share | — | — | — | — | — |